title: Everolimus-eluting stents and paclitaxel-eluting stents in patients presenting with myocardial infarction: insights from the two-year results of the COMPARE prospective randomised controlled trial.
abstract: OBJECTIVE
  Although large clinical trials have shown that everolimus-eluting stents (EES) significantly reduce target vessel revascularisation (TVR), myocardial infarction (MI) and stent thrombosis (ST) compared to paclitaxel-eluting stents (PES) in diverse populations, there is a paucity of data comparing EES and PES in patients presenting with MI.
  
  
  RESULTS
  We performed a post hoc subgroup analysis on COMPARE, an all-comer trial comparing EES to PES. We identified 863 patients (EES=434, PES=429 treated for MI: 452 ST-elevation MI (STEMI) and 411 non ST-elevation MI (NSTEMI). EES was associated with a significant reduction in the primary endpoint, a composite of all-cause mortality, MI, and TVR, at two years (RR=0.57; 95% CI: 0.40-0.83, p=0.002). While the effect was more marked in the STEMI (RR=0.51; 95% CI: 0.30-0.87, p=0.01) than the NSTEMI subgroup (RR=0.65; 95% CI: 0.39-1.08, p=0.09), the interaction p-value (0.5) suggests that a difference in treatment effect between presentations is unlikely. ST rates were significantly lower with EES (RR=0.30; 95% CI: 0.12-0.73, p=0.005).
  
  
  CONCLUSIONS
  At two years, EES results are superior to PES in terms of safety and efficacy endpoints in treatment of MI.
authors.affiliation: Department of Cardiology, Maasstad Ziekenhuis, Rotterdam, The Netherlands. kedhie@maasstadziekenhuis.nl
authors.forename: Elvin
authors.initials: E
authors.lastname: Kedhi
authors.forename: Marc
authors.initials: M
authors.lastname: Gomes
authors.forename: Kaiyum Sheik
authors.initials: KS
authors.lastname: Joesoef
authors.forename: Jochem
authors.initials: J
authors.lastname: Wassing
authors.forename: Dick
authors.initials: D
authors.lastname: Goedhart
authors.forename: Eugene
authors.initials: E
authors.lastname: McFadden
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
mesh_terms: D000368:Aged; D054855:Drug-Eluting Stents; D004562:Electrocardiography; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus